mRNA level of ROCK1, RHOA, and LIMK2 as genes associated with apoptosis in evaluation of effectiveness of adalimumab treatment.

Abstract

BACKGROUND:

Psoriasis is a multifactorial autoimmune disease, which underlies the abnormalities of the apoptotic process. In cases of psoriasis and psoriatic arthritis, biological treatment is used. This study aimed to determine any changes in the expression of the genes associated with apoptosis in patients with psoriatic arthritis treated with adalimumab and to assess any phenotypic modifications based on changes in dermatological indexes.

METHODS:

The study included 20 patients with psoriatic arthritis treated biologically and 20 healthy volunteers. The research material consisted of peripheral blood mononuclear cells (PBMCs) from which the total RNA was isolated. Changes in the gene expression were determined using oligonucleotide microarrays and RT-qPCR. The clinical condition was assessed based on selected indicators: PASI, BSA [%], DAS28, and DLQI, which were determined every 3 months.

RESULTS:

There were changes in the expression of genes associated with apoptosis. Significant differences were found for ROCK1, RhoA, and LIMK2 expression profiles in PBMCs. At the initial stage of treatment, a decrease in the PASI and BSA rates was observed. At the later stages, the values of these indicators increased once again. There were correlations between the changes in these genes' expression and the dermatological markers.

CONCLUSION:

Adalimumab influences the expression of genes related to apoptosis and the values of dermatological indicators of patients. Changes in the expression level of genes associated with apoptosis suggest that ROCK1, RhoA, and LIMK2 may be genes that can potentially be indicators of treatment effectiveness and lack of response to biological treatment.

• Authors: Agata Krawczyk, Barbara Strzałka-Mrozik, Beniamin Grabarek, Dominika Wcisło-Dziadecka, Magdalena Kimsa-Dudek, Celina Kruszniewska-Rajs, Joanna Gola
• Journal: Pharmacological reports : PR (Pharmacol Rep) Vol. 72 Issue 2 Pg. 389-399 (Apr 2020) ISSN: 2299-5684 [Electronic] Switzerland
• PMID: 32124389 (Publication Type: Journal Article)

Chemical References

• Antirheumatic Agents
• RNA, Messenger
• RHOA protein, human
• LIMK2 protein, human
• Lim Kinases
• ROCK1 protein, human
• rho-Associated Kinases
• rhoA GTP-Binding Protein
• Adalimumab

Topics

• Adalimumab (administration & dosage, therapeutic use)
• Antirheumatic Agents (administration & dosage, therapeutic use)
• Apoptosis (drug effects, genetics)
• Arthritis, Psoriatic (blood, drug therapy, genetics)
• Case-Control Studies
• Healthy Volunteers
• Humans
• Leukocytes, Mononuclear (drug effects, metabolism)
• Lim Kinases (genetics)
• RNA, Messenger (genetics)
• Treatment Outcome
• rho-Associated Kinases (genetics)
• rhoA GTP-Binding Protein (genetics)